|Bid||7.86 x 0|
|Ask||7.89 x 0|
|Day's Range||7.53 - 7.88|
|52 Week Range||3.70 - 9.29|
|Beta (3Y Monthly)||4.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.26|
Analysts' Ratings for ACB, CRON, and APHA in February(Continued from Prior Part)Aurora CannabisAurora Cannabis (ACB) has been almost flat since it reported its earnings on February 11. To learn more about the company’s earnings, read Aurora
Analysts' Ratings for ACB, CRON, and APHA in February(Continued from Prior Part)Cronos Group Cronos Group (CRON) hasn’t reported its earnings yet. Cronos Group has been one of the top choices for investors (HMMJ) along with Canopy Growth (WEED),
PALM BEACH, Florida, Feb. 20, 2019 /CNW/ -- In 2018 the U.S. Farm bill opened the floodgates and effectively launched the CBD business to never before seen heights, and the projections reflect the consumers' acceptance of CBD infused products. It may also be that with the millennials and the growing number of seniors buying CBD infused products, the projection may actually need to be updated! A recent article in FORBES opined that: " with CBD sales in the US expected to reach $22 billion by 2022, as projected by (a) cannabis market research company. It was also the year "CBD gummies" reached No. 3 on Google's most popular search terms.
Canaccord Genuity Raises Price Target for Canopy GrowthCanaccord Genuity raises price targetOn February 18, Canopy Growth (WEED) received a price target upgrade from Canaccord Genuity after the company reported its Q3 earnings on February 14.
Over the last year, Canada approved its recreational use. Corporate America is using cannabinoids and hemp oil in everything from lotions and pain balm to beverages. President Trump signed the 2018 Farm Bill into law.
Key Takeaways from Canopy Growth's Q3 Earnings CallCanopy Growth’s earningsOn February 14, Canopy Growth (WEED) (CGC) reported its earnings. The company held an earnings call the next day. We discussed the earnings call and summarized the key
NYSE-A: HEXO) is pleased to announce it has entered into a syndicated credit facility with Canadian Imperial Bank of Commerce (“CIBC”), as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent (together with CIBC, the “Lenders”). Under the terms of the credit facility, the Lenders will provide HEXO up to C$65 million of secured debt financing at a rate of interest that is expected to average in the mid-to-high 5% per annum range over its three-year term.
Is Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) or HEXO Corp. (TSX:HEXO) a better pot stock to buy today?
Analyzing Canopy Growth's Q3 Results(Continued from Prior Part)Margins During the third quarter, Canopy Growth (WEED) (CGC) reported a gross margin of ~12.4 million Canadian dollars, which was lower compared to 16.5 million Canadian dollars in the
Markets have been off to a roaring start this year; however, these five stocks have fared even better, including licensed cannabis producer HEXO Corp (TSX:HEXO) -- up more than 53% through the first six weeks of 2019.
Analysts' Ratings for WEED, TLRY, and APHA in February(Continued from Prior Part)Sales to grow Canopy Growth (WEED) (CGC) is scheduled to announce its third-quarter earnings on February 14 after the market closes. Canopy Growth is expected to see
Aurora Cannabis: Key Takeaways from Its Q2 Earnings(Continued from Prior Part)Gross margins fell In the second quarter, Aurora Cannabis (ACB) reported nearly 363% YoY (year-over-year) and 83% sequential sales growth. The company reported gross
Cannabis Stocks Hit Pause Last WeekWeekly performanceIn the week ending February 8, cannabis stocks ended in the red. The Horizons Marijuana Life Sciences ETF (HMMJ) fell nearly 2.8% from the closing on February 1. The Emerging Marijuana Growers
Do Cannabis Stocks Look Expensive?(Continued from Prior Part)Other cannabis companies Previously in this series, we compared four cannabis stocks’ forward EV-to-sales multiples. In this part, we’ll discuss the other five cannabis stocks.
VIVO Cannabis Inc. (TSX:VIVO) is trading with some attractive valuations at the moment, but do two other weed stocks offer more upside?
Aphria Inc. (TSX:APH)(NYSE:APH) and HEXO Corp. (TSX:HEXO) are potential takeover targets in the cannabis sector. Is one a better bet right now?
What to Expect from Canopy Growth's Q3 EarningsCanopy Growth’s upcoming earnings Canopy Growth (WEED) (CGC) is scheduled to announce its third-quarter earnings on February 14 after the market closes. The company is one of the most valuable
Curaleaf Is Up ~40% in 2019: Is There More Upside?(Continued from Prior Part)Analysts’ recommendations Of the three analysts that cover Curaleaf Holdings (CURLF), two are favoring a “strong buy,” and one is favoring a “buy.” On average,
Why Analysts Expect Tilray to Report a Loss in the Fourth QuarterTilray to report earnings According to NASDAQ, Tilray (TLRY) is set to report its fourth-quarter earnings next week, on February 12. Let’s look at analysts’ expectations for the
With proponents claiming that it can treat ailments as diverse as inflammation, pain, cancer, insomnia, anxiety, and depression, it's no surprise that it's already impacting major industries, like the $4.2 trillion wellness market. In fact, CBD is already showing up in spa, wellness and skincare industry products. ''Hemp-derived CBD has been touted in several medical studies as having a myriad of health benefits ranging from treating psoriasis, atopic dermatitis and eczema to minimizing seizures, stress, and insomnia,'' notes Forbes.